(Q37947906)

25 August 2017

Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin (English)

1 reference

25 August 2017

0 references

1 reference

1 reference

1 reference

Vuk Stambolic

2

0 references

Pamela J Goodwin

object named as

Pamela J Goodwin

series ordinal

1

0 references

publication date

1 October 2011

1 reference

25 August 2017

1 reference

25 August 2017

20 Suppl 3

1 reference

25 August 2017

S31-5

1 reference

Minireview: Obesity and breast cancer: the estrogen connection

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Insulin-lowering effects of metformin in women with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Metformin in breast cancer: time for action

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

IGF and insulin receptor signaling in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Metformin and reduced risk of cancer in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Sulphonylureas and cancer: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Diabetes mellitus and risk of breast cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Energetics in colorectal and prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Metabolic syndrome as a prognostic factor for breast cancer recurrences

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Associations of insulin resistance and adiponectin with mortality in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Metabolic profile, physical activity, and mortality in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Metformin prevents tobacco carcinogen--induced lung tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970291-0

7 January 2021

10.1016/S0960-9776(11)70291-0

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

22015290